Revlimid_BPA

The Department of Veterans Affairs (VA), through Network Contracting Office 15, awarded a 12-month Blanket Purchase Agreement (BPA) to Bristol-Myers Squibb for the brand-name pharmaceutical REVLIMID® (lenalidomide) capsules, commencing February 2, 2026, and ending February 1, 2027. This BPA was established as a sole-source 8(a) set-aside under GSAM/R 538.7104-3 due to the unique and highly specialized nature of REVLIMID®, which is subject to the FDA-mandated Lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program. The sole source award reflects the clinical necessity of using the brand-name product for certain patients intolerant to generic alternatives and the restrictive distribution requirements that limit supply to REMS-certified pharmacies. The program ensures uninterrupted access to the medication across the VA’s Veterans Integrated Service Networks (VISNs), replacing an expiring McKesson contract. This BPA is situated under Bristol-Myers Squibb's Federal Supply Schedule (FSS) contract and does not include option periods, indicating an interim emergency acquisition to avoid treatment disruptions. The procurement is governed by compliance with REMS-certified dispensing, strict brand-name exclusivity, and FDA requirements, with a focus on patient safety and supply chain reliability. Key administrative contacts include contracting officers and specialists located at the VA contracting office in Leavenworth, KS, while delivery and acceptance occur at VA medical centers and REMS-certified pharmacies nationwide. Pricing details and specific contract values were not disclosed, but the award is based on a best-value trade-off emphasizing regulatory compliance, product uniqueness, and clinical imperatives rather than low cost. Inspection and acceptance rely primarily on adherence to REMS protocols and FDA specifications rather than physical inspection standards. Overall, the contract underscores a specialized federal procurement tailored to the unique pharmaceutical and clinical needs of the Veterans Health Administration.